The effects of melatonin supplementation on inflammatory markers among patients with metabolic syndrome or related disorders: a systematic review and meta-analysis of randomized controlled trials

Maryam Akbari, Vahidreza Ostadmohammadi, Reza Tabrizi, Kamran B. Lankarani, Seyed Taghi Heydari, Elaheh Amirani, Russel J Reiter, Zatollah Asemi

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objective: This systematic review and meta-analysis of randomized controlled trials (RCTs) was carried out to determine the effect of melatonin supplementation on the inflammatory markers among individuals with metabolic syndrome (MetS) and related disorders. Methods: We searched the following databases up to March 2018: PubMed, MEDLINE, EMBASE, Web of Science, and Cochrane Central Register of Controlled Trials. Three reviewers independently assessed study eligibility, extracted data, and evaluated risk of bias of included primary studies. Statistical heterogeneity was assessed using Cochran’s Q test and I-square (I2) statistic. Data were pooled using the random effect model and standardized mean difference (SMD) was considered as the summary effect size. Results: Six trials of 317 potential reports were identified to be suitable for our meta-analysis. The pooled results using random effects model indicated that melatonin supplementation significantly reduced C-reactive protein (CRP) (SMD = − 1.80; 95% CI − 3.27, − 0.32; P = 0.01; I2: 95.2) and interleukin 6 (IL-6) concentrations (SMD = − 2.02; 95% CI − 3.57, − 0.47; P = 0.01; I2: 91.2) among patients with MetS and related disorders; however, it did not affect tumor necrosis factor-α (TNF-α) concentrations (SMD = − 1.87; 95% CI − 3.81, 0.07; P = 0.05; I2: 94.4). Conclusions: In summary, the current meta-analysis showed the promising effect of melatonin administration on reducing CRP and IL-6, but not TNF-α levels among patients with MetS and related disorders. Additional prospective studies are recommended using higher supplementation doses and longer intervention period.

Original languageEnglish (US)
Pages (from-to)1-9
Number of pages9
JournalInflammopharmacology
DOIs
StateAccepted/In press - Jun 15 2018

Fingerprint

Melatonin
Meta-Analysis
Randomized Controlled Trials
C-Reactive Protein
Interleukin-6
Tumor Necrosis Factor-alpha
PubMed
MEDLINE
Databases
Prospective Studies

Keywords

  • Inflammatory markers
  • Melatonin
  • Meta-analysis

ASJC Scopus subject areas

  • Immunology
  • Pharmacology
  • Pharmacology (medical)

Cite this

The effects of melatonin supplementation on inflammatory markers among patients with metabolic syndrome or related disorders : a systematic review and meta-analysis of randomized controlled trials. / Akbari, Maryam; Ostadmohammadi, Vahidreza; Tabrizi, Reza; Lankarani, Kamran B.; Heydari, Seyed Taghi; Amirani, Elaheh; Reiter, Russel J; Asemi, Zatollah.

In: Inflammopharmacology, 15.06.2018, p. 1-9.

Research output: Contribution to journalArticle

Akbari, Maryam ; Ostadmohammadi, Vahidreza ; Tabrizi, Reza ; Lankarani, Kamran B. ; Heydari, Seyed Taghi ; Amirani, Elaheh ; Reiter, Russel J ; Asemi, Zatollah. / The effects of melatonin supplementation on inflammatory markers among patients with metabolic syndrome or related disorders : a systematic review and meta-analysis of randomized controlled trials. In: Inflammopharmacology. 2018 ; pp. 1-9.
@article{156654fca58b4e688471369a55fe6997,
title = "The effects of melatonin supplementation on inflammatory markers among patients with metabolic syndrome or related disorders: a systematic review and meta-analysis of randomized controlled trials",
abstract = "Objective: This systematic review and meta-analysis of randomized controlled trials (RCTs) was carried out to determine the effect of melatonin supplementation on the inflammatory markers among individuals with metabolic syndrome (MetS) and related disorders. Methods: We searched the following databases up to March 2018: PubMed, MEDLINE, EMBASE, Web of Science, and Cochrane Central Register of Controlled Trials. Three reviewers independently assessed study eligibility, extracted data, and evaluated risk of bias of included primary studies. Statistical heterogeneity was assessed using Cochran’s Q test and I-square (I2) statistic. Data were pooled using the random effect model and standardized mean difference (SMD) was considered as the summary effect size. Results: Six trials of 317 potential reports were identified to be suitable for our meta-analysis. The pooled results using random effects model indicated that melatonin supplementation significantly reduced C-reactive protein (CRP) (SMD = − 1.80; 95{\%} CI − 3.27, − 0.32; P = 0.01; I2: 95.2) and interleukin 6 (IL-6) concentrations (SMD = − 2.02; 95{\%} CI − 3.57, − 0.47; P = 0.01; I2: 91.2) among patients with MetS and related disorders; however, it did not affect tumor necrosis factor-α (TNF-α) concentrations (SMD = − 1.87; 95{\%} CI − 3.81, 0.07; P = 0.05; I2: 94.4). Conclusions: In summary, the current meta-analysis showed the promising effect of melatonin administration on reducing CRP and IL-6, but not TNF-α levels among patients with MetS and related disorders. Additional prospective studies are recommended using higher supplementation doses and longer intervention period.",
keywords = "Inflammatory markers, Melatonin, Meta-analysis",
author = "Maryam Akbari and Vahidreza Ostadmohammadi and Reza Tabrizi and Lankarani, {Kamran B.} and Heydari, {Seyed Taghi} and Elaheh Amirani and Reiter, {Russel J} and Zatollah Asemi",
year = "2018",
month = "6",
day = "15",
doi = "10.1007/s10787-018-0508-7",
language = "English (US)",
pages = "1--9",
journal = "Inflammopharmacology",
issn = "0925-4692",
publisher = "Birkhauser Verlag Basel",

}

TY - JOUR

T1 - The effects of melatonin supplementation on inflammatory markers among patients with metabolic syndrome or related disorders

T2 - a systematic review and meta-analysis of randomized controlled trials

AU - Akbari, Maryam

AU - Ostadmohammadi, Vahidreza

AU - Tabrizi, Reza

AU - Lankarani, Kamran B.

AU - Heydari, Seyed Taghi

AU - Amirani, Elaheh

AU - Reiter, Russel J

AU - Asemi, Zatollah

PY - 2018/6/15

Y1 - 2018/6/15

N2 - Objective: This systematic review and meta-analysis of randomized controlled trials (RCTs) was carried out to determine the effect of melatonin supplementation on the inflammatory markers among individuals with metabolic syndrome (MetS) and related disorders. Methods: We searched the following databases up to March 2018: PubMed, MEDLINE, EMBASE, Web of Science, and Cochrane Central Register of Controlled Trials. Three reviewers independently assessed study eligibility, extracted data, and evaluated risk of bias of included primary studies. Statistical heterogeneity was assessed using Cochran’s Q test and I-square (I2) statistic. Data were pooled using the random effect model and standardized mean difference (SMD) was considered as the summary effect size. Results: Six trials of 317 potential reports were identified to be suitable for our meta-analysis. The pooled results using random effects model indicated that melatonin supplementation significantly reduced C-reactive protein (CRP) (SMD = − 1.80; 95% CI − 3.27, − 0.32; P = 0.01; I2: 95.2) and interleukin 6 (IL-6) concentrations (SMD = − 2.02; 95% CI − 3.57, − 0.47; P = 0.01; I2: 91.2) among patients with MetS and related disorders; however, it did not affect tumor necrosis factor-α (TNF-α) concentrations (SMD = − 1.87; 95% CI − 3.81, 0.07; P = 0.05; I2: 94.4). Conclusions: In summary, the current meta-analysis showed the promising effect of melatonin administration on reducing CRP and IL-6, but not TNF-α levels among patients with MetS and related disorders. Additional prospective studies are recommended using higher supplementation doses and longer intervention period.

AB - Objective: This systematic review and meta-analysis of randomized controlled trials (RCTs) was carried out to determine the effect of melatonin supplementation on the inflammatory markers among individuals with metabolic syndrome (MetS) and related disorders. Methods: We searched the following databases up to March 2018: PubMed, MEDLINE, EMBASE, Web of Science, and Cochrane Central Register of Controlled Trials. Three reviewers independently assessed study eligibility, extracted data, and evaluated risk of bias of included primary studies. Statistical heterogeneity was assessed using Cochran’s Q test and I-square (I2) statistic. Data were pooled using the random effect model and standardized mean difference (SMD) was considered as the summary effect size. Results: Six trials of 317 potential reports were identified to be suitable for our meta-analysis. The pooled results using random effects model indicated that melatonin supplementation significantly reduced C-reactive protein (CRP) (SMD = − 1.80; 95% CI − 3.27, − 0.32; P = 0.01; I2: 95.2) and interleukin 6 (IL-6) concentrations (SMD = − 2.02; 95% CI − 3.57, − 0.47; P = 0.01; I2: 91.2) among patients with MetS and related disorders; however, it did not affect tumor necrosis factor-α (TNF-α) concentrations (SMD = − 1.87; 95% CI − 3.81, 0.07; P = 0.05; I2: 94.4). Conclusions: In summary, the current meta-analysis showed the promising effect of melatonin administration on reducing CRP and IL-6, but not TNF-α levels among patients with MetS and related disorders. Additional prospective studies are recommended using higher supplementation doses and longer intervention period.

KW - Inflammatory markers

KW - Melatonin

KW - Meta-analysis

UR - http://www.scopus.com/inward/record.url?scp=85048543345&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048543345&partnerID=8YFLogxK

U2 - 10.1007/s10787-018-0508-7

DO - 10.1007/s10787-018-0508-7

M3 - Article

C2 - 29907916

AN - SCOPUS:85048543345

SP - 1

EP - 9

JO - Inflammopharmacology

JF - Inflammopharmacology

SN - 0925-4692

ER -